Effect of the Medicare Part D coverage gap on medication use among patients with hypertension and hyperlipidemia

Annals of Internal Medicine

Volumn 156, Issue 11, 2012, Pages 776-784

  Li, Pengxiang ^a   McElligott, Sean ^a   Bergquist, Henry ^b   Sanford Schwartz, J ^b   Doshi, Jalpa A ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; ANTACID AGENT; ANTIDEPRESSANT AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; GENERIC DRUG;

AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; CONTROLLED STUDY; DEMOGRAPHY; DRUG COST; DRUG USE; FEMALE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MEDICARE; PATIENT COMPLIANCE; PRESCRIPTION; PRIORITY JOURNAL; QUASI EXPERIMENTAL STUDY; SYMPTOM;

EID: 84861899843     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/0003-4819-156-11-201206050-00004     Document Type: Article

References (37)

1. Thom T, Haase N, Rosamond W, Howard VJ, Rumsfeld J, Manolio T, et al; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2006;113:e85-151. [PMID: 16407573]
2. Blustein J. Drug coverage and drug purchases by Medicare beneficiaries with hypertension. Health Aff (Millwood). 2000;19:219-30. [PMID: 10718036]
3. Adams AS, Soumerai SB, Ross-Degnan D. Use of antihypertensive drugs by Medicare enrollees: does type of drug coverage matter? Health Aff (Millwood). 2001;20:276-86. [PMID: 11194852]
4. Federman AD, Adams AS, Ross-Degnan D, Soumerai SB, Ayanian JZ. Supplemental insurance and use of effective cardiovascular drugs among elderly medicare beneficiaries with coronary heart disease. JAMA. 2001;286:1732-9. [PMID: 11594898]
5. Kaiser Family Foundation. Explaining Health Care Reform: Key Changes to the Medicare Part D Drug Benefit Coverage Gap. Menlo Park, CA: Kaiser Family Foundation; 2010.
6. Fung V, Mangione CM, Huang J, Turk N, Quiter ES, Schmittdiel JA, et al. Falling into the coverage gap: Part D drug costs and adherence for Medicare Advantage prescription drug plan beneficiaries with diabetes. Health Serv Res. 2010;45:355-75. [PMID: 20050931]
7. Sun SX, Lee KY. The Medicare Part D doughnut hole: effect on pharmacy utilization. Manag Care Interface. 2007;20:59; 51-5. [PMID: 18161394]
8. Cronk A, Humphries TL, Delate T, Clark D, Morris B. Medication strategies used by Medicare beneficiaries who reach the Part D standard drug-benefit threshold. Am J Health Syst Pharm. 2008;65:1062-70. [PMID: 18499881]
9. Hsu J, Fung V, Price M, Huang J, Brand R, Hui R, et al. Medicare beneficiaries' knowledge of Part D prescription drug program benefits and responses to drug costs. JAMA. 2008;299:1929-36. [PMID: 18430912]
10. Pedan A, Lu J, Varasteh LT. Assessment of drug consumption patterns for Medicare Part D patients. Am J Manag Care. 2009;15:323-7. [PMID: 19435400]
11. Raebel MA, Delate T, Ellis JL, Bayliss EA. Effects of reaching the drug benefit threshold on Medicare members' healthcare utilization during the first year of Medicare Part D. Med Care. 2008;46:1116-22. [PMID: 18815534]
12. Schneeweiss S, Patrick AR, Pedan A, Varasteh L, Levin R, Liu N, et al. The effect of Medicare Part D coverage on drug use and cost sharing among seniors without prior drug benefits. Health Aff (Millwood). 2009;28:w305-16. [PMID: 19189990]
13. Zhang Y, Donohue JM, Newhouse JP, Lave JR. The effects of the coverage gap on drug spending: a closer look at Medicare Part D. Health Aff (Millwood). 2009;28:w317-25. [PMID: 19189991]
14. Gu Q, Zeng F, Patel BV, Tripoli LC. Part D coverage gap and adherence to diabetes medications. Am J Manag Care. 2010;16:911-8. [PMID: 21348561]
15. Shadish WR, Cook TD, Campbell DT. Experimental and Quasi-Experimental Designs for Generalized Causal Inference. Boston: Houghton Mifflin; 2002.
16. Campbell DT, Stanley JC. Experimental and Quasi-Experimental Designs for Research. Boston: Houghton Mifflin; 1965.
17. Peterson AM, Nau DP, Cramer JA, Benner J, Gwadry-Sridhar F, Nichol M. A checklist for medication compliance and persistence studies using retrospective databases. Value Health. 2007;10:3-12. [PMID: 17261111]
18. Hsu J, Price M, Huang J, Brand R, Fung V, Hui R, et al. Unintended consequences of caps on Medicare drug benefits. N Engl J Med. 2006;354:2349-59. [PMID: 16738271]
19. Schneeweiss S, Patrick AR, Maclure M, Dormuth CR, Glynn RJ. Adherence to statin therapy under drug cost sharing in patients with and without acute myocardial infarction: a population-based natural experiment. Circulation. 2007; 115:2128-35. [PMID: 17420348]
20. Sikka R, Xia F, Aubert RE. Estimating medication persistency using administrative claims data. Am J Manag Care. 2005;11:449-57. [PMID: 16044982]
21. Robst J, Levy JM, Ingber MJ. Diagnosis-based risk adjustment for medicare prescription drug plan payments. Health Care Financ Rev. 2007;28:15-30. [PMID: 17722748]
22. Rosenbaum PR. Model-based direct adjustment. J Am Stat Assoc. 1987;82: 387-94.
23. Austin PC. The relative ability of different propensity score methods to balance measured covariates between treated and untreated subjects in observational studies. Med Decis Making. 2009;29:661-77. [PMID: 19684288]
24. Saftlas H, Diller W. Industry Surveys. Healthcare: Pharmaceuticals. New York: Standard & Poor's; 2007. Accessed at www.nd.edu/~scorwin/fin70610 /S&PIndustryReport_Pharmaceuticals.pdf on 30 January 2012.
25. Hoadley J, Summer L, Hargrave E, Cubanski J, Neuman T. Medicare Part D 2010 Data Spotlight: The Coverage Gap. Menlo Park, CA: Kaiser Family Foundation; 2009. Accessed at www.kff.org/medicare/upload/8008.pdf on 30 January 2012.
26. Heidelbaugh JJ, Goldberg KL, Inadomi JM. Overutilization of proton pump inhibitors: a review of cost-effectiveness and risk [corrected]. Am J Gastroenterol. 2009;104 Suppl 2:S27-32. [PMID: 19262544]
27. Glew CM, Rentler RJ. Use of proton pump inhibitors and other acid suppressive medications in newly admitted nursing facility patients. J Am Med Dir Assoc. 2007;8:607-9. [PMID: 17998118]
28. Zink DA, Pohlman M, Barnes M, Cannon ME. Long-term use of acid suppression started inappropriately during hospitalization. Aliment Pharmacol Ther. 2005;21:1203-9. [PMID: 15882240]
29. Nardino RJ, Vender RJ, Herbert PN. Overuse of acid-suppressive therapy in hospitalized patients. Am J Gastroenterol. 2000;95:3118-22. [PMID: 11095327]
30. Gupta R, Garg P, Kottoor R, Munoz JC, Jamal MM, Lambiase LR, et al. Overuse of acid suppression therapy in hospitalized patients. South Med J. 2010; 103:207-11. [PMID: 20134378]
31. Piette JD, Heisler M, Horne R, Caleb Alexander G. A conceptually based approach to understanding chronically ill patients' responses to medication cost pressures. Soc Sci Med. 2006;62:846-57. [PMID: 16095789]
32. Doshi JA, Brandt N, Stuart B. The impact of drug coverage on COX-2 inhibitor use in Medicare. Health Aff (Millwood). 2004;Suppl Web Exclusives: W4: 94-105. [PMID: 15451967]
33. Fendrick AM, Smith DG, Chernew ME, Shah SN. A benefit-based copay for prescription drugs: patient contribution based on total benefits, not drug acquisition cost. Am J Manag Care. 2001;7:861-7. [PMID: 11570020]
34. Steiner JF, Koepsell TD, Fihn SD, Inui TS. A general method of compliance assessment using centralized pharmacy records. Description and validation. Med Care. 1988;26:814-23. [PMID: 3398608]
35. Steiner JF, Prochazka AV. The assessment of refill compliance using pharmacy records: methods, validity, and applications. J Clin Epidemiol. 1997;50: 105-16. [PMID: 9048695]
36. Stuart BC, Doshi JA, Terza JV. Assessing the impact of drug use on hospital costs. Health Serv Res. 2009;44:128-44. [PMID: 18783453]
37. Wooldridge JM. Econometric Analysis of Cross Section and Panel Data. Cambridge, MA: MIT Pr; 2001.